OXBT Stock – Why Oxygen Biotherapeutics Boomed Over 30%

Its new cardia drug is preparing for a phase 3 trial

   

OXBT Stock – Why Oxygen Biotherapeutics Boomed Over 30%

The publication of protocols for a phase 3 trial for Oxygen Biotherapeutics’ (OXBT) cardiac treatment Levosimendan sent OXBT stock surging more than 32% on Monday morning.

heart monitor still alive not dead 630 300x199 OXBT Stock   Why Oxygen Biotherapeutics Boomed Over 30%
Source: Flickr

Oxygen Biotherapeutics said that the phase 3 trial will be conducted by Duke University’s Duke Clinical Research Institute. The randomized, double-blind study will involve an estimated 760 patients at 50 cardiac care centers across the U.S.

pills spilling prescription bottle 630 flickr 200x200 OXBT Stock   Why Oxygen Biotherapeutics Boomed Over 30%
FDA Rejects Sanofi Multiple Sclerosis Drug

Protocols for the phase 3 trial have been published on clinicaltrials.gov.

Levosimendan is designed to reduce death rates among cardiac surgery patients who are vulnerable to low cardiac output syndrome (LCOS).

Between February and October OXBT stock fell by more than 80%. However, OXBT stock rallied somewhat in November before sliding modestly before the end of 2013.


Article printed from InvestorPlace Media, http://investorplace.com/2014/01/oxbt-stock-oxygen-biotherapeutics-boomed-30/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.